Cargando…

Iguratimod Ameliorates the Severity of Secondary Progressive Multiple Sclerosis in Model Mice by Directly Inhibiting IL-6 Production and Th17 Cell Migration via Mitigation of Glial Inflammation

SIMPLE SUMMARY: We previously developed a novel model of progressive multiple sclerosis, called progressive experimental autoimmune encephalomyelitis, in mice with oligodendroglia-specific knockout of the connexin-47 gene. Our previous research showed that iguratimod, an antirheumatic drug, effectiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nagata, Satoshi, Yamasaki, Ryo, Takase, Ezgi Ozdemir, Iida, Kotaro, Watanabe, Mitsuru, Masaki, Katsuhisa, Wijering, Marion Heleen Cathérine, Yamaguchi, Hiroo, Kira, Jun-ichi, Isobe, Noriko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10525689/ https://www.ncbi.nlm.nih.gov/pubmed/37759616 http://dx.doi.org/10.3390/biology12091217

Ejemplares similares

Early and extensive alterations of glial connexins, distal oligodendrogliopathy type demyelination, and nodal/paranodal pathology are characteristic of multiple system atrophy
por: Nishimura, Yuji, et al.
Publicado: (2022)

Connexin 30 Deficiency Attenuates Chronic but Not Acute Phases of Experimental Autoimmune Encephalomyelitis Through Induction of Neuroprotective Microglia
por: Fang, Mei, et al.
Publicado: (2018)

Novel disease-modifying anti-rheumatic drug iguratimod suppresses chronic experimental autoimmune encephalomyelitis by down-regulating activation of macrophages/microglia through an NF-κB pathway
por: Li, Guangrui, et al.
Publicado: (2018)

Connexin 30 Deficiency Ameliorates Disease Progression at the Early Phase in a Mouse Model of Amyotrophic Lateral Sclerosis by Suppressing Glial Inflammation
por: Hashimoto, Yu, et al.
Publicado: (2022)

Association of Decreased Percentage of Vδ2(+)Vγ9(+) γδ T Cells With Disease Severity in Multiple Sclerosis
por: Maimaitijiang, Guzailiayi, et al.
Publicado: (2018)

Brain gray matter astroglia-specific connexin 43 ablation attenuates spinal cord inflammatory demyelination
por: Une, Hayato, et al.
Publicado: (2021)

Genetic factors for susceptibility to and manifestations of neuromyelitis optica
por: Matsushita, Takuya, et al.
Publicado: (2020)

Long-term use of interferon-β in multiple sclerosis increases Vδ1(−)Vδ2(−)Vγ9(−) γδ T cells that are associated with a better outcome
por: Maimaitijiang, Guzailiayi, et al.
Publicado: (2019)

A new clustering method identifies multiple sclerosis‐specific T‐cell receptors
por: Hayashi, Fumie, et al.
Publicado: (2021)

Th1 cells downregulate connexin 43 gap junctions in astrocytes via microglial activation
por: Watanabe, Mitsuru, et al.
Publicado: (2016)

Oral phase dysphagia in facial onset sensory and motor neuronopathy
por: Watanabe, Mitsuru, et al.
Publicado: (2018)

Preparation of a Major Metabolite of Iguratimod and Simultaneous Assay of Iguratimod and Its Metabolite by HPLC in Rat Plasma
por: Han, Jun-ping, et al.
Publicado: (2019)

Serum Anti-oligodendrocyte Autoantibodies in Patients With Multiple Sclerosis Detected by a Tissue-Based Immunofluorescence Assay
por: Miyachi, Yukino, et al.
Publicado: (2021)

Iguratimod efficacy in palindromic rheumatism treatment
por: Yuan, Fangfang, et al.
Publicado: (2023)

Efficacy and Safety of Iguratimod for the Treatment of Rheumatoid Arthritis
por: Li, Jiangtao, et al.
Publicado: (2013)

Early strong intrathecal inflammation in cerebellar type multiple system atrophy by cerebrospinal fluid cytokine/chemokine profiles: a case control study
por: Yamasaki, Ryo, et al.
Publicado: (2017)

Two susceptible HLA-DRB1 alleles for multiple sclerosis differentially regulate anti-JC virus antibody serostatus along with fingolimod
por: Watanabe, Mitsuru, et al.
Publicado: (2020)

Genetic and Infectious Profiles Influence Cerebrospinal Fluid IgG Abnormality in Japanese Multiple Sclerosis Patients
por: Yoshimura, Satoshi, et al.
Publicado: (2014)

Iguratimod Inhibits the Aggressiveness of Rheumatoid Fibroblast-Like Synoviocytes
por: Lin, Jin, et al.
Publicado: (2019)

Iguratimod alleviates tubulo-interstitial injury in mice with lupus
por: Xue, Leixi, et al.
Publicado: (2022)

Connexin 30 deficiency attenuates A2 astrocyte responses and induces severe neurodegeneration in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride Parkinson’s disease animal model
por: Fujita, Atsushi, et al.
Publicado: (2018)

Genetic and Infectious Profiles of Japanese Multiple Sclerosis Patients
por: Yoshimura, Satoshi, et al.
Publicado: (2012)

Iguratimod as a New Drug for Rheumatoid Arthritis: Current Landscape
por: Xie, Sisi, et al.
Publicado: (2020)

Characteristic Cerebrospinal Fluid Cytokine/Chemokine Profiles in Neuromyelitis Optica, Relapsing Remitting or Primary Progressive Multiple Sclerosis
por: Matsushita, Takuya, et al.
Publicado: (2013)

Painful trigeminal neuropathy associated with anti-Plexin D1 antibody
por: Fujii, Takayuki, et al.
Publicado: (2020)

Clearance of peripheral nerve misfolded mutant protein by infiltrated macrophages correlates with motor neuron disease progression
por: Shiraishi, Wataru, et al.
Publicado: (2021)

Corrigendum: Iguratimod as a New Drug for Rheumatoid Arthritis: Current Landscape
por: Xie, Sisi, et al.
Publicado: (2020)

Allergic Skin Rash Caused by Iguratimod: A Report of Two Cases
por: Lu, Wentian, et al.
Publicado: (2022)

Downregulation of Neuronal and Dendritic Connexin36-Made Electrical Synapses Without Glutamatergic Axon Terminals in Spinal Anterior Horn Cells From the Early Stage of Amyotrophic Lateral Sclerosis
por: Kobayakawa, Yuko, et al.
Publicado: (2018)

Contribution of cortical lesions to cognitive impairment in Japanese patients with multiple sclerosis
por: Shinoda, Koji, et al.
Publicado: (2020)

Ciclesonide/iguratimod: Prolonged presence of SARS-CoV-2: case report
Publicado: (2020)

Randomised, Double-Blind, Placebo-Controlled Study of Iguratimod in the Treatment of Active Spondyloarthritis
por: Li, Yan, et al.
Publicado: (2021)

Influence of Iguratimod on Bone Metabolism in Patients with Rheumatoid Arthritis: A Meta-analysis
por: Deng, Li, et al.
Publicado: (2022)

Iguratimod as an alternative therapy for systemic sclerosis and prevention of the occurrence of ischemic digital ulcer
por: Yan, Qingran, et al.
Publicado: (2023)

Shadowboxing-induced reflex seizures in a patient with focal epilepsy
por: Okadome, Toshiki, et al.
Publicado: (2022)

Peripheral Blood T Cell Dynamics Predict Relapse in Multiple Sclerosis Patients on Fingolimod
por: Song, Zi-Ye, et al.
Publicado: (2015)

Connexin 43 Astrocytopathy Linked to Rapidly Progressive Multiple Sclerosis and Neuromyelitis Optica
por: Masaki, Katsuhisa, et al.
Publicado: (2013)

Prevention of Immune Nephritis by the Small Molecular Weight Immunomodulator Iguratimod in MRL/lpr Mice
por: Yan, Qingran, et al.
Publicado: (2014)

Iguratimod as an alternative induction therapy for refractory lupus nephritis: a preliminary investigational study
por: Kang, Yuening, et al.
Publicado: (2020)

Conflict between efficacy and economy in rheumatoid arthritis treatment: Iguratimod is found at a compromise
por: Tanaka, Masao
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9c2i9ka9dlqq8ugkq3f24k5225